LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells

Cancer Research

Volumn 71, Issue 23, 2011, Pages 7301-7311

  Ward, Yvona ^a   Lake, Ross ^a   Yin, Juan Juan ^a   Heger, Christopher D ^a   Raffeld, Mark ^a   Goldsmith, Paul K ^a   Merino, Maria ^a   Kelly, Kathleen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD97 ANTIGEN; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; RHO FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; BONE METASTASIS; CANCER CELL; CELL INVASION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; HETERODIMERIZATION; HUMAN; HUMAN CELL; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTIGENS, CD; CELL LINE, TUMOR; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, G12-G13; GUANOSINE TRIPHOSPHATE; HUMANS; LYSOPHOSPHOLIPIDS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOPHOSPHATIDIC ACID; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 82655171586     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2381     Document Type: Article

References (39)

1. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, et al. CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 1996;157: 5438-47. (Pubitemid 126448963)
2. Yona S, Lin HH, Siu WO, Gordon S, Stacey M. Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 2008;33:491-500.
3. Aust G, Steinert M, Schutz A, Boltze C, Wahlbuhl M, Hamann J, et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol 2002;118:699-707. (Pubitemid 37046314)
4. Steinert M, Wobus M, Boltze C, Schutz A, Wahlbuhl M, Hamann J, et al. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 2002;161:1657-67. (Pubitemid 35265525)
5. Mustafa T, Eckert A, Klonisch T, Kehlen A, Maurer P, Klintschar M, et al. Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2005;14:108-19. (Pubitemid 40165290)
6. Loberg RD, Wojno KJ, Day LL, Pienta KJ. Analysis of membrane-bound complement regulatory proteins in prostate cancer. Urology 2005;66:1321-6. (Pubitemid 41797325)
7. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008;7:339-57.
8. Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, Itoh H. Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. J Biol Chem 2008;283:14469-78.
9. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A 2006;103:9023-8. (Pubitemid 43902526)
10. Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007;450:430-4. (Pubitemid 350126756)
11. Silva JP, Lelianova V, Hopkins C, Volynski KE, Ushkaryov Y. Functional cross-interaction of the fragments produced by the cleavage of distinct adhesion G-protein-coupled receptors. J Biol Chem 2009; 284:6495-506.
12. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counter receptors on endothelial cells. Blood 2005;105:2836-44. (Pubitemid 40446277)
13. Hamann J, Vogel B, van Schijndel GM, van Lier RA. The seven-span transmembrane receptorCD97has a cellular ligand (CD55, DAF). J Exp Med 1996;184:1185-9. (Pubitemid 26313577)
14. Kwakkenbos MJ, Pouwels W, Matmati M, Stacey M, Lin HH, Gordon S, et al. Expression of the largest CD97 andEMR2isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol 2005;77:112-9. (Pubitemid 40310699)
15. Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010;91:130-8.
16. Stortelers C, Kerkhoven R, Moolenaar WH. Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics 2008;9:387.
17. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223-32.
18. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, Sud N, et al. Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 2006;147:4883-92. (Pubitemid 44402195)
19. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, et al. Overexpression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004;6:R640-6.
20. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, andmetastases. Cancer Cell 2009;15:539-50.
21. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 2007;27:7538-50. (Pubitemid 350033659)
22. Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, et al. Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry 2010;49:2235-45.
23. Yang GC, Wan LS, Papellas J, Waisman J. Compact cell blocks. Use for body fluids, fine needle aspirations and endometrial brush biopsies. Acta Cytol 1998;42:703-6. (Pubitemid 28274781)
24. Ward Y, Spinelli B, Quon MJ, Chen H, Ikeda SR, Kelly K. Phosphorylation of critical serine residues in Gem separates cytoskeletal reorganization from down-regulation of calcium channel activity. Mol Cell Biol 2004;24:651-61. (Pubitemid 38057917)
25. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 2001;21:5958-69. (Pubitemid 32737812)
26. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, et al. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 2007;47:53-87.
27. Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS. The small GTP-binding protein Rho links G protein-coupled receptors and Galpha12 to the serum response element and to cellular transformation. Proc Natl Acad Sci U S A 1997;94:10098-103.
28. Hao F, Tan M, Xu X, Han J,Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta 2007;1771: 883-92.
29. Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal 2008;20:1320-8.
30. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 2001;159:579-90. (Pubitemid 32751088)
31. Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 2005;62:180-94. (Pubitemid 41572701)
32. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004;279:28970-8. (Pubitemid 38915766)
33. Shida D, Kitayama J, Yamaguchi H, Hama K, Aoki J, Arai H, et al. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells. Exp Cell Res 2004;301:168-78. (Pubitemid 39504970)
34. Thymiakou E, Episkopou V. Detection of signaling effector-complexes downstream of bmp4 using PLA, a proximity ligation assay. J Vis Exp 2011. pii: 2631.
35. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25. (Pubitemid 40385527)
36. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-76. (Pubitemid 39600573)
37. Levoye A, Dam J, Ayoub MA, Guillaume JL, Jockers R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep 2006;7:1094-8. (Pubitemid 44660563)
38. Gupte R, PatilR, Liu J, Wang Y, Lee SC, Fujiwara Y, et al.Benzyl and naphthalenemethylphosphonic acid inhibitors of autotaxinwith anti-invasive and anti-metastatic activity. ChemMedChem 2011;6: 922-35.
39. Davies JQ, Lin HH, Stacey M, Yona S, Chang GW, Gordon S, et al. Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncol Rep 2011;25:619-27.